Skip links

Zolgensma® (onasemnogene abeparvovec-xioi)

Full Name Zolgensma® (onasemnogene abeparvovec-xioi)
Drug Zolgensma
Manufacturer Novartis Gene Therapy
Route of Administration Intravenous
Site of Care Healthcare Facility
Approved Indication The treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene
Disease Spinal Muscular Atrophy (SMA)
Therapeutic Area Neurology; Cell & Gene Therapy
Referral Link Zolgensma Referral Form
Phone Number 800-697-5048
Fax Number 877-471-5704
Website zolgensma.com